More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward

Kyle Blankenship

Ironwood Pharmaceuticals has walked a less-than-easy path the past few years with a proxy-driven shakeup and multiple clinical failures rocking the company. Now under new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

More than a year af­ter trim­ming R&D unit, Iron­wood adds a rare dis­ease drug to the pipeline in hope­ful step for­ward

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward